ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Valeant To Buy Branded Generics Assets From Gerot Lannach

DOW JONES NEWSWIRES Valeant Pharmaceuticals International Inc. (VRX) said Tuesday it's acquiring from Austria's Gerot Lannach certain branded generics assets that generate the bulk of their sales in Russia. Mississauga, Ont.-based Valeant said the assets generated net revenue of about $55 million last year. Gerot Lannach's largest product is acetylsalicylic acid, a low-dose aspirin. Valeant said it will pay less than three times sales, and may make up to an additional $20 million in milestone payments, based upon future performance objectives. As part of the transaction, Valeant and Gerot Lannach will enter into a strategic partnership that includes an exclusive 10-year supply agreement for the acquired products and the opportunity for Valeant to introduce additional Gerot Lannach products into Valeant territories such as its emerging markets in Southeast Asia and Latin America. Valeant expects the transaction to boost results starting immediately. -By Carolyn King, Dow Jones Newswires; 416-306-2100; carolyn.m.king@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
05/25/201501:00:00Pharming and Cytobioteck Announce Distribution Agreement for...
05/23/201512:03:02Billionaire George Soros Just Sold These 3 Stocks: Should You?
05/21/201516:48:48Initial Statement of Beneficial Ownership (3)
05/19/201517:00:00Valeant Pharmaceuticals Announces 2015 Annual Meeting Results
05/19/201517:00:00Valeant Pharmaceuticals Announces 2015 Annual Meeting Results
05/19/201516:59:40Current Report Filing (8-k)
05/18/201512:18:57Endo to Buy Generics Maker Par Pharma for $8 Billion -- 4th Update
05/18/201511:05:26Endo to Buy Generics Maker Par Pharma for $8 Billion -- 3rd Update
05/18/201501:00:00Pharming and Clinigen Group Initiate "HAEi GAP" Global Access...
05/15/201522:41:08
05/15/201519:55:34Third Point Sells Entire $1 Billion Stake in Alibaba
05/15/201519:42:17Hedge Fund Dumps Alibaba
05/12/201516:05:00Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders
05/12/201516:05:00Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders
05/10/201514:18:02Meet the Company That May Become Healthcare's Version of Berkshire...
05/10/201513:03:02Investors Just Doubled Their Money on This Stock
05/06/201517:53:12Statement of Changes in Beneficial Ownership (4)
05/05/201516:58:55Statement of Changes in Beneficial Ownership (4)
05/04/201519:26:00From Einhorn to Ackman, Live From the Ira Sohn Conference...
04/30/201515:43:06Quarterly Report (10-q)

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad